Primary Biliary Cholangitis Market Report 2026

Primary Biliary Cholangitis Market Overview

• Primary Biliary Cholangitis market size has reached to $1.06 billion in 2025 • Expected to grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 8.7% • Growth Driver: Surge In Liver Cancer Cases Fuels Growth In Primary Biliary Cholangitis Market • Market Trend: Innovative Orphan Drug Combinations Transforming the Landscape of Primary Biliary Cholangitis (PBC) Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the primary biliary cholangitis market include: • Drugs (Segmentation By Treatment Type) → Expected gain of $557.78 Million • Hospitals (Segmentation By End-Users) → Expected gain of $267.78 Million • Specialty Clinics (Segmentation By End-Users) → Expected gain of $158.22 Million

What Is Covered Under Primary Biliary Cholangitis Market?

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive inflammation and destruction of the small bile ducts within the liver. This condition can lead to impaired bile flow, liver damage, and various related complications. PBC primarily affects middle-aged women and is often associated with symptoms such as fatigue, itching, and abdominal discomfort. The main types of treatment for primary biliary cholangitis are drugs and liver transplantation. A drug is any chemical substance that causes a change in an organism's physiology or psychology when consumed, and ursodeoxycholic acid (UDCA) is the standard first-line treatment for PBC, which helps improve liver function, reduce liver inflammation, and slow down disease progression. Primary biliary cholangitis is diagnosed through imaging tests such as magnetic resonance elastography (MRE), magnetic resonance cholangiopancreatography (MRCP), ultrasound, fibroscan, blood tests, cholesterol tests, antibody tests, liver tests, and others by end users such as specialty clinics, homecare, and others.

What Is The Primary Biliary Cholangitis Market Growth Forecast?

The primary biliary cholangitis market size is expected to see strong growth in the next few years. It will grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing investments in rare disease research, rising adoption of personalized medicine approaches, expansion of advanced imaging diagnostics, growing pipeline of targeted therapies, increasing focus on early-stage disease management. Major trends in the forecast period include increasing focus on targeted drug therapies, rising adoption of advanced diagnostic imaging techniques, growing integration of biomarker-based disease monitoring, expansion of personalized treatment approaches, enhanced emphasis on early disease detection.

What Is The Driver Of The Primary Biliary Cholangitis Market?

The surge in liver cancer is expected to propel the growth of the primary biliary cholangitis market going forward. Liver cancer, also known is a type of cancer that begins in the cells of the liver. The role of primary biliary cholangitis in liver cancer is significant due to the increased risk of various malignancies, including cholangiocarcinoma and hepatocellular carcinoma. The growing prevalence of the disease and its potential complications contribute to the growth of the primary biliary cholangitis market. For instance, in January 2024, the American Cancer Society, a leading professional organization in the U.S., projected approximately 41,630 new cases of liver cancer in the country, with 28,000 cases in men and 13,630 in women. Additionally, about 29,840 individuals (19,120 men and 10,720 women) are expected to succumb to this disease. Therefore, the surge in liver cancer is driving the growth of the primary biliary cholangitis industry.

How Will The Drivers Impact Growth In The Global Primary Biliary Cholangitis Market?

• Increasing Healthcare Expenditure (Low) – The increasing healthcare expenditure will become a key driver of growth in the primary biliary cholangitis market by 2030. Increased funding supports pharmaceutical innovation, enhances treatments, and advances clinical research. Better insurance coverage and reimbursement improve access to therapies, while expanded healthcare infrastructure facilitates early detection and treatment, increasing patient adoption. As a result, the increasing healthcare expenditure is anticipated to contributing to a 0.8% annual growth in the market. • Growing Geriatric Population (Low) – The growing geriatric population will emerge as a major factor driving the expansion of the primary biliary cholangitis market by 2030. PBC primarily affects older adults, particularly women, and its prevalence increases with aging. This growing demographic fuels demand for advanced diagnostics and treatments, as elderly individuals are more susceptible to autoimmune and liver diseases. Consequently, the growing geriatric population is projected to contributing to a 0.8% annual growth in the market. • Surge In Liver Cancer (Low) – The surge in liver cancer will serve as a key growth catalyst for the primary biliary cholangitis market by 2030, PBC leads to bile duct inflammation, increasing the risk of cirrhosis and hepatocellular carcinoma (HCC). As more patients progress to liver cancer, demand for effective treatments rises. Proper PBC management is crucial for successful liver transplants, further boosting the need for targeted therapies. Therefore, this surge in liver cancer is projected to supporting to a 0.5% annual growth in the market.

How Will The Restraints Impact Growth In The Global Primary Biliary Cholangitis Market?

• Inadequate Response To First-Line Treatment (Low) – Inadequate Response To First-Line Treatment will restrict the growth of the Primary Biliary Cholangitis market during the forecast period. Many PBC patients do not respond adequately to first-line therapies, requiring alternative treatment options. The lack of effective treatment options for non-responders creates unmet medical needs and affects patient outcomes. Treatment resistance can limit the effectiveness of available therapies and reduce market growth.

Key Players In The Global Primary Biliary Cholangitis Market

Major companies operating in the primary biliary cholangitis market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck And Co Inc, Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Dr Reddys Laboratories Ltd, Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Intercept Pharmaceuticals Inc, Arrowhead Pharmaceuticals Inc, Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc, Albireo Pharma Inc, Genfit SA, CymaBay Therapeutics Inc, Ascletis Pharma Inc, Ipsen Pharma, Ferring Pharmaceuticals

Global Primary Biliary Cholangitis Market Trends and Insights

Major companies operating in the primary biliary cholangitis market are focused on developing innovative and specialized treatments, such as orphan drugs with a combination of obeticholic acid (OCA) and bezafibrates to treat primary biliary cholangitis (PBC), to gain market exclusivity. The combination of OCA and bezafibrate with an orphan drug designation aims to offer a more comprehensive and effective approach to managing PBC treatment, potentially improving the quality of life for individuals affected by this rare condition. For instance, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, received orphan drug designation from the FDA for the combination of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, as a potential treatment for primary biliary cholangitis (PBC), a progressive liver disease, and obeticholic acid (marketed as Ocaliva) is approved for PBC in the US.

What Are Latest Mergers And Acquisitions In The Primary Biliary Cholangitis Market?

In March 2023, Ipsen SA, a France-based pharmaceutical company, acquired Albireo Pharma, Inc. for an undisclosed sum. With this acquisition, Ipsen aims to expand its rare disease portfolio with novel pipeline prospects, promising therapies for rare cholestatic liver illnesses in both children and adults, and strong scientific and commercial capabilities. Albireo Pharma Inc. is a US-based biopharmaceutical company developing A3907 therapy for primary biliary cholangitis (PBC).

What Defines the Primary Biliary Cholangitis Market?

The primary biliary cholangitis market includes revenues earned by entities by providing services such as psychosocial support services, nutritional guidance services, medical diagnosis, and specialized medical care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary biliary cholangitis market also includes sales of products such as fat-soluble vitamins, anti-itch medications, and imaging equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Primary Biliary Cholangitis Market Report 2026?

The primary biliary cholangitis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the primary biliary cholangitis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.